Mechanisms of antiproteinuric effects of azelnidipine in hypertensive patients with type 2 diabetes mellitus

Trial Profile

Mechanisms of antiproteinuric effects of azelnidipine in hypertensive patients with type 2 diabetes mellitus

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2014

At a glance

  • Drugs Azelnidipine (Primary) ; Amlodipine; Angiotensin receptor antagonists
  • Indications Essential hypertension; Proteinuria
  • Focus Pharmacodynamics
  • Acronyms MAP in DM
  • Most Recent Events

    • 13 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top